nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadodiamide—Gadobenate Dimeglumine—ALB—liver cancer	0.0236	0.5	CrCbGaD
Gadodiamide—Gadofosveset trisodium—ALB—liver cancer	0.0236	0.5	CrCbGaD
Gadodiamide—Myocardial ischaemia—Sorafenib—liver cancer	0.0226	0.0237	CcSEcCtD
Gadodiamide—Warmth—Epirubicin—liver cancer	0.0211	0.0221	CcSEcCtD
Gadodiamide—Warmth—Doxorubicin—liver cancer	0.0195	0.0205	CcSEcCtD
Gadodiamide—Renal failure acute—Sorafenib—liver cancer	0.0143	0.015	CcSEcCtD
Gadodiamide—Cardiac failure—Sorafenib—liver cancer	0.0135	0.0142	CcSEcCtD
Gadodiamide—Hyponatraemia—Sorafenib—liver cancer	0.0132	0.0139	CcSEcCtD
Gadodiamide—Venous thrombosis—Epirubicin—liver cancer	0.0124	0.013	CcSEcCtD
Gadodiamide—Venous thrombosis—Doxorubicin—liver cancer	0.0115	0.0121	CcSEcCtD
Gadodiamide—Acute coronary syndrome—Sorafenib—liver cancer	0.01	0.0105	CcSEcCtD
Gadodiamide—Renal failure—Sorafenib—liver cancer	0.00999	0.0105	CcSEcCtD
Gadodiamide—Myocardial infarction—Sorafenib—liver cancer	0.00996	0.0105	CcSEcCtD
Gadodiamide—Neuropathy peripheral—Sorafenib—liver cancer	0.00996	0.0105	CcSEcCtD
Gadodiamide—Lung disorder—Epirubicin—liver cancer	0.00948	0.00995	CcSEcCtD
Gadodiamide—Urinary tract disorder—Sorafenib—liver cancer	0.00901	0.00945	CcSEcCtD
Gadodiamide—Urethral disorder—Sorafenib—liver cancer	0.00894	0.00938	CcSEcCtD
Gadodiamide—Lung disorder—Doxorubicin—liver cancer	0.00877	0.00921	CcSEcCtD
Gadodiamide—Rash erythematous—Epirubicin—liver cancer	0.00876	0.0092	CcSEcCtD
Gadodiamide—Feeling hot—Epirubicin—liver cancer	0.00855	0.00897	CcSEcCtD
Gadodiamide—Tinnitus—Sorafenib—liver cancer	0.0085	0.00892	CcSEcCtD
Gadodiamide—Flushing—Sorafenib—liver cancer	0.00846	0.00888	CcSEcCtD
Gadodiamide—Ageusia—Epirubicin—liver cancer	0.00828	0.00869	CcSEcCtD
Gadodiamide—Rigors—Epirubicin—liver cancer	0.00822	0.00863	CcSEcCtD
Gadodiamide—Injection site pain—Epirubicin—liver cancer	0.00822	0.00863	CcSEcCtD
Gadodiamide—Arrhythmia—Sorafenib—liver cancer	0.00815	0.00855	CcSEcCtD
Gadodiamide—Rash erythematous—Doxorubicin—liver cancer	0.00811	0.00851	CcSEcCtD
Gadodiamide—Feeling hot—Doxorubicin—liver cancer	0.00791	0.0083	CcSEcCtD
Gadodiamide—Dysgeusia—Sorafenib—liver cancer	0.00777	0.00816	CcSEcCtD
Gadodiamide—Extravasation—Epirubicin—liver cancer	0.00769	0.00807	CcSEcCtD
Gadodiamide—Ageusia—Doxorubicin—liver cancer	0.00766	0.00804	CcSEcCtD
Gadodiamide—Vasodilation procedure—Epirubicin—liver cancer	0.00764	0.00802	CcSEcCtD
Gadodiamide—Vasodilation—Epirubicin—liver cancer	0.00764	0.00802	CcSEcCtD
Gadodiamide—Cardiovascular disorder—Epirubicin—liver cancer	0.00764	0.00802	CcSEcCtD
Gadodiamide—Injection site pain—Doxorubicin—liver cancer	0.00761	0.00798	CcSEcCtD
Gadodiamide—Rigors—Doxorubicin—liver cancer	0.00761	0.00798	CcSEcCtD
Gadodiamide—Syncope—Sorafenib—liver cancer	0.00712	0.00747	CcSEcCtD
Gadodiamide—Extravasation—Doxorubicin—liver cancer	0.00712	0.00747	CcSEcCtD
Gadodiamide—Vasodilation—Doxorubicin—liver cancer	0.00707	0.00742	CcSEcCtD
Gadodiamide—Vasodilation procedure—Doxorubicin—liver cancer	0.00707	0.00742	CcSEcCtD
Gadodiamide—Cardiovascular disorder—Doxorubicin—liver cancer	0.00707	0.00742	CcSEcCtD
Gadodiamide—Loss of consciousness—Sorafenib—liver cancer	0.00698	0.00732	CcSEcCtD
Gadodiamide—Coordination abnormal—Epirubicin—liver cancer	0.00683	0.00717	CcSEcCtD
Gadodiamide—Arthralgia—Sorafenib—liver cancer	0.00676	0.00709	CcSEcCtD
Gadodiamide—Myalgia—Sorafenib—liver cancer	0.00676	0.00709	CcSEcCtD
Gadodiamide—Injection site reaction—Epirubicin—liver cancer	0.00667	0.007	CcSEcCtD
Gadodiamide—Dry mouth—Sorafenib—liver cancer	0.00661	0.00694	CcSEcCtD
Gadodiamide—Eructation—Epirubicin—liver cancer	0.00659	0.00692	CcSEcCtD
Gadodiamide—Melaena—Epirubicin—liver cancer	0.00656	0.00688	CcSEcCtD
Gadodiamide—Anaphylactic shock—Sorafenib—liver cancer	0.00648	0.0068	CcSEcCtD
Gadodiamide—Infection—Sorafenib—liver cancer	0.00644	0.00676	CcSEcCtD
Gadodiamide—Shock—Sorafenib—liver cancer	0.00637	0.00669	CcSEcCtD
Gadodiamide—Nervous system disorder—Sorafenib—liver cancer	0.00635	0.00667	CcSEcCtD
Gadodiamide—Coordination abnormal—Doxorubicin—liver cancer	0.00632	0.00664	CcSEcCtD
Gadodiamide—Injection site reaction—Doxorubicin—liver cancer	0.00617	0.00648	CcSEcCtD
Gadodiamide—Coma—Epirubicin—liver cancer	0.00613	0.00644	CcSEcCtD
Gadodiamide—Eructation—Doxorubicin—liver cancer	0.0061	0.0064	CcSEcCtD
Gadodiamide—Melaena—Doxorubicin—liver cancer	0.00607	0.00637	CcSEcCtD
Gadodiamide—Musculoskeletal discomfort—Sorafenib—liver cancer	0.0059	0.00619	CcSEcCtD
Gadodiamide—Abnormal vision—Epirubicin—liver cancer	0.00585	0.00614	CcSEcCtD
Gadodiamide—Dyspnoea—Sorafenib—liver cancer	0.00578	0.00606	CcSEcCtD
Gadodiamide—Dyspepsia—Sorafenib—liver cancer	0.0057	0.00599	CcSEcCtD
Gadodiamide—Coma—Doxorubicin—liver cancer	0.00567	0.00596	CcSEcCtD
Gadodiamide—Phlebitis—Epirubicin—liver cancer	0.00565	0.00593	CcSEcCtD
Gadodiamide—Fatigue—Sorafenib—liver cancer	0.00559	0.00586	CcSEcCtD
Gadodiamide—Pain—Sorafenib—liver cancer	0.00554	0.00581	CcSEcCtD
Gadodiamide—Abnormal vision—Doxorubicin—liver cancer	0.00542	0.00568	CcSEcCtD
Gadodiamide—Gastrointestinal pain—Sorafenib—liver cancer	0.0053	0.00556	CcSEcCtD
Gadodiamide—Renal failure acute—Epirubicin—liver cancer	0.00528	0.00554	CcSEcCtD
Gadodiamide—Phlebitis—Doxorubicin—liver cancer	0.00523	0.00549	CcSEcCtD
Gadodiamide—Hot flush—Epirubicin—liver cancer	0.00521	0.00547	CcSEcCtD
Gadodiamide—Menopausal symptoms—Epirubicin—liver cancer	0.00516	0.00542	CcSEcCtD
Gadodiamide—Urticaria—Sorafenib—liver cancer	0.00515	0.0054	CcSEcCtD
Gadodiamide—Abdominal pain—Sorafenib—liver cancer	0.00512	0.00538	CcSEcCtD
Gadodiamide—Body temperature increased—Sorafenib—liver cancer	0.00512	0.00538	CcSEcCtD
Gadodiamide—Renal impairment—Epirubicin—liver cancer	0.00512	0.00537	CcSEcCtD
Gadodiamide—Anaphylactoid reaction—Epirubicin—liver cancer	0.00503	0.00528	CcSEcCtD
Gadodiamide—Cardiac failure—Epirubicin—liver cancer	0.00499	0.00524	CcSEcCtD
Gadodiamide—Hyponatraemia—Epirubicin—liver cancer	0.00489	0.00513	CcSEcCtD
Gadodiamide—Renal failure acute—Doxorubicin—liver cancer	0.00488	0.00512	CcSEcCtD
Gadodiamide—Hot flush—Doxorubicin—liver cancer	0.00482	0.00506	CcSEcCtD
Gadodiamide—Migraine—Epirubicin—liver cancer	0.00479	0.00503	CcSEcCtD
Gadodiamide—Menopausal symptoms—Doxorubicin—liver cancer	0.00478	0.00501	CcSEcCtD
Gadodiamide—Hypersensitivity—Sorafenib—liver cancer	0.00477	0.00501	CcSEcCtD
Gadodiamide—Renal impairment—Doxorubicin—liver cancer	0.00474	0.00497	CcSEcCtD
Gadodiamide—Anaphylactoid reaction—Doxorubicin—liver cancer	0.00466	0.00489	CcSEcCtD
Gadodiamide—Asthenia—Sorafenib—liver cancer	0.00465	0.00488	CcSEcCtD
Gadodiamide—Cardiac failure—Doxorubicin—liver cancer	0.00462	0.00485	CcSEcCtD
Gadodiamide—Pruritus—Sorafenib—liver cancer	0.00458	0.00481	CcSEcCtD
Gadodiamide—Ataxia—Epirubicin—liver cancer	0.00458	0.00481	CcSEcCtD
Gadodiamide—Blood creatinine increased—Epirubicin—liver cancer	0.00456	0.00479	CcSEcCtD
Gadodiamide—Hyponatraemia—Doxorubicin—liver cancer	0.00453	0.00475	CcSEcCtD
Gadodiamide—Migraine—Doxorubicin—liver cancer	0.00444	0.00466	CcSEcCtD
Gadodiamide—Diarrhoea—Sorafenib—liver cancer	0.00443	0.00465	CcSEcCtD
Gadodiamide—Dizziness—Sorafenib—liver cancer	0.00428	0.0045	CcSEcCtD
Gadodiamide—Ataxia—Doxorubicin—liver cancer	0.00424	0.00445	CcSEcCtD
Gadodiamide—Blood creatinine increased—Doxorubicin—liver cancer	0.00422	0.00443	CcSEcCtD
Gadodiamide—Vomiting—Sorafenib—liver cancer	0.00412	0.00432	CcSEcCtD
Gadodiamide—Rash—Sorafenib—liver cancer	0.00408	0.00429	CcSEcCtD
Gadodiamide—Dermatitis—Sorafenib—liver cancer	0.00408	0.00428	CcSEcCtD
Gadodiamide—Headache—Sorafenib—liver cancer	0.00406	0.00426	CcSEcCtD
Gadodiamide—Nausea—Sorafenib—liver cancer	0.00385	0.00404	CcSEcCtD
Gadodiamide—Renal failure—Epirubicin—liver cancer	0.00369	0.00387	CcSEcCtD
Gadodiamide—Neuropathy peripheral—Epirubicin—liver cancer	0.00368	0.00386	CcSEcCtD
Gadodiamide—Renal failure—Doxorubicin—liver cancer	0.00341	0.00358	CcSEcCtD
Gadodiamide—Neuropathy peripheral—Doxorubicin—liver cancer	0.0034	0.00357	CcSEcCtD
Gadodiamide—Rhinitis—Epirubicin—liver cancer	0.00338	0.00355	CcSEcCtD
Gadodiamide—Pharyngitis—Epirubicin—liver cancer	0.00334	0.00351	CcSEcCtD
Gadodiamide—Urinary tract disorder—Epirubicin—liver cancer	0.00333	0.00349	CcSEcCtD
Gadodiamide—Urethral disorder—Epirubicin—liver cancer	0.0033	0.00347	CcSEcCtD
Gadodiamide—Visual impairment—Epirubicin—liver cancer	0.00325	0.00341	CcSEcCtD
Gadodiamide—Tinnitus—Epirubicin—liver cancer	0.00314	0.0033	CcSEcCtD
Gadodiamide—Flushing—Epirubicin—liver cancer	0.00313	0.00328	CcSEcCtD
Gadodiamide—Rhinitis—Doxorubicin—liver cancer	0.00313	0.00328	CcSEcCtD
Gadodiamide—Pharyngitis—Doxorubicin—liver cancer	0.00309	0.00325	CcSEcCtD
Gadodiamide—Urinary tract disorder—Doxorubicin—liver cancer	0.00308	0.00323	CcSEcCtD
Gadodiamide—Urethral disorder—Doxorubicin—liver cancer	0.00306	0.00321	CcSEcCtD
Gadodiamide—Chills—Epirubicin—liver cancer	0.00302	0.00317	CcSEcCtD
Gadodiamide—Arrhythmia—Epirubicin—liver cancer	0.00301	0.00316	CcSEcCtD
Gadodiamide—Visual impairment—Doxorubicin—liver cancer	0.00301	0.00315	CcSEcCtD
Gadodiamide—Tinnitus—Doxorubicin—liver cancer	0.00291	0.00305	CcSEcCtD
Gadodiamide—Flushing—Doxorubicin—liver cancer	0.00289	0.00304	CcSEcCtD
Gadodiamide—Dysgeusia—Epirubicin—liver cancer	0.00287	0.00302	CcSEcCtD
Gadodiamide—Chills—Doxorubicin—liver cancer	0.0028	0.00294	CcSEcCtD
Gadodiamide—Arrhythmia—Doxorubicin—liver cancer	0.00279	0.00292	CcSEcCtD
Gadodiamide—Ill-defined disorder—Epirubicin—liver cancer	0.00272	0.00286	CcSEcCtD
Gadodiamide—Dysgeusia—Doxorubicin—liver cancer	0.00266	0.00279	CcSEcCtD
Gadodiamide—Malaise—Epirubicin—liver cancer	0.00265	0.00278	CcSEcCtD
Gadodiamide—Syncope—Epirubicin—liver cancer	0.00263	0.00276	CcSEcCtD
Gadodiamide—Loss of consciousness—Epirubicin—liver cancer	0.00258	0.00271	CcSEcCtD
Gadodiamide—Convulsion—Epirubicin—liver cancer	0.00254	0.00267	CcSEcCtD
Gadodiamide—Ill-defined disorder—Doxorubicin—liver cancer	0.00252	0.00264	CcSEcCtD
Gadodiamide—Arthralgia—Epirubicin—liver cancer	0.0025	0.00262	CcSEcCtD
Gadodiamide—Chest pain—Epirubicin—liver cancer	0.0025	0.00262	CcSEcCtD
Gadodiamide—Myalgia—Epirubicin—liver cancer	0.0025	0.00262	CcSEcCtD
Gadodiamide—Anxiety—Epirubicin—liver cancer	0.00249	0.00261	CcSEcCtD
Gadodiamide—Discomfort—Epirubicin—liver cancer	0.00247	0.00259	CcSEcCtD
Gadodiamide—Malaise—Doxorubicin—liver cancer	0.00245	0.00257	CcSEcCtD
Gadodiamide—Dry mouth—Epirubicin—liver cancer	0.00244	0.00256	CcSEcCtD
Gadodiamide—Syncope—Doxorubicin—liver cancer	0.00243	0.00255	CcSEcCtD
Gadodiamide—Anaphylactic shock—Epirubicin—liver cancer	0.00239	0.00251	CcSEcCtD
Gadodiamide—Oedema—Epirubicin—liver cancer	0.00239	0.00251	CcSEcCtD
Gadodiamide—Loss of consciousness—Doxorubicin—liver cancer	0.00239	0.0025	CcSEcCtD
Gadodiamide—Infection—Epirubicin—liver cancer	0.00238	0.0025	CcSEcCtD
Gadodiamide—Shock—Epirubicin—liver cancer	0.00236	0.00247	CcSEcCtD
Gadodiamide—Convulsion—Doxorubicin—liver cancer	0.00235	0.00247	CcSEcCtD
Gadodiamide—Nervous system disorder—Epirubicin—liver cancer	0.00235	0.00246	CcSEcCtD
Gadodiamide—Tachycardia—Epirubicin—liver cancer	0.00234	0.00245	CcSEcCtD
Gadodiamide—Hyperhidrosis—Epirubicin—liver cancer	0.00231	0.00243	CcSEcCtD
Gadodiamide—Chest pain—Doxorubicin—liver cancer	0.00231	0.00243	CcSEcCtD
Gadodiamide—Myalgia—Doxorubicin—liver cancer	0.00231	0.00243	CcSEcCtD
Gadodiamide—Arthralgia—Doxorubicin—liver cancer	0.00231	0.00243	CcSEcCtD
Gadodiamide—Anxiety—Doxorubicin—liver cancer	0.0023	0.00242	CcSEcCtD
Gadodiamide—Discomfort—Doxorubicin—liver cancer	0.00228	0.0024	CcSEcCtD
Gadodiamide—Dry mouth—Doxorubicin—liver cancer	0.00226	0.00237	CcSEcCtD
Gadodiamide—Hypotension—Epirubicin—liver cancer	0.00224	0.00235	CcSEcCtD
Gadodiamide—Anaphylactic shock—Doxorubicin—liver cancer	0.00222	0.00233	CcSEcCtD
Gadodiamide—Oedema—Doxorubicin—liver cancer	0.00222	0.00233	CcSEcCtD
Gadodiamide—Infection—Doxorubicin—liver cancer	0.0022	0.00231	CcSEcCtD
Gadodiamide—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00218	0.00229	CcSEcCtD
Gadodiamide—Shock—Doxorubicin—liver cancer	0.00218	0.00229	CcSEcCtD
Gadodiamide—Nervous system disorder—Doxorubicin—liver cancer	0.00217	0.00228	CcSEcCtD
Gadodiamide—Tachycardia—Doxorubicin—liver cancer	0.00216	0.00227	CcSEcCtD
Gadodiamide—Paraesthesia—Epirubicin—liver cancer	0.00215	0.00226	CcSEcCtD
Gadodiamide—Hyperhidrosis—Doxorubicin—liver cancer	0.00214	0.00225	CcSEcCtD
Gadodiamide—Dyspnoea—Epirubicin—liver cancer	0.00213	0.00224	CcSEcCtD
Gadodiamide—Somnolence—Epirubicin—liver cancer	0.00213	0.00223	CcSEcCtD
Gadodiamide—Dyspepsia—Epirubicin—liver cancer	0.00211	0.00221	CcSEcCtD
Gadodiamide—Hypotension—Doxorubicin—liver cancer	0.00207	0.00217	CcSEcCtD
Gadodiamide—Fatigue—Epirubicin—liver cancer	0.00206	0.00217	CcSEcCtD
Gadodiamide—Pain—Epirubicin—liver cancer	0.00205	0.00215	CcSEcCtD
Gadodiamide—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00202	0.00212	CcSEcCtD
Gadodiamide—Paraesthesia—Doxorubicin—liver cancer	0.00199	0.00209	CcSEcCtD
Gadodiamide—Dyspnoea—Doxorubicin—liver cancer	0.00198	0.00207	CcSEcCtD
Gadodiamide—Feeling abnormal—Epirubicin—liver cancer	0.00197	0.00207	CcSEcCtD
Gadodiamide—Somnolence—Doxorubicin—liver cancer	0.00197	0.00207	CcSEcCtD
Gadodiamide—Gastrointestinal pain—Epirubicin—liver cancer	0.00196	0.00205	CcSEcCtD
Gadodiamide—Dyspepsia—Doxorubicin—liver cancer	0.00195	0.00205	CcSEcCtD
Gadodiamide—Fatigue—Doxorubicin—liver cancer	0.00191	0.002	CcSEcCtD
Gadodiamide—Urticaria—Epirubicin—liver cancer	0.0019	0.002	CcSEcCtD
Gadodiamide—Pain—Doxorubicin—liver cancer	0.00189	0.00199	CcSEcCtD
Gadodiamide—Body temperature increased—Epirubicin—liver cancer	0.00189	0.00199	CcSEcCtD
Gadodiamide—Abdominal pain—Epirubicin—liver cancer	0.00189	0.00199	CcSEcCtD
Gadodiamide—Feeling abnormal—Doxorubicin—liver cancer	0.00183	0.00192	CcSEcCtD
Gadodiamide—Gastrointestinal pain—Doxorubicin—liver cancer	0.00181	0.0019	CcSEcCtD
Gadodiamide—Hypersensitivity—Epirubicin—liver cancer	0.00176	0.00185	CcSEcCtD
Gadodiamide—Urticaria—Doxorubicin—liver cancer	0.00176	0.00185	CcSEcCtD
Gadodiamide—Abdominal pain—Doxorubicin—liver cancer	0.00175	0.00184	CcSEcCtD
Gadodiamide—Body temperature increased—Doxorubicin—liver cancer	0.00175	0.00184	CcSEcCtD
Gadodiamide—Asthenia—Epirubicin—liver cancer	0.00172	0.0018	CcSEcCtD
Gadodiamide—Pruritus—Epirubicin—liver cancer	0.00169	0.00178	CcSEcCtD
Gadodiamide—Diarrhoea—Epirubicin—liver cancer	0.00164	0.00172	CcSEcCtD
Gadodiamide—Hypersensitivity—Doxorubicin—liver cancer	0.00163	0.00171	CcSEcCtD
Gadodiamide—Asthenia—Doxorubicin—liver cancer	0.00159	0.00167	CcSEcCtD
Gadodiamide—Dizziness—Epirubicin—liver cancer	0.00158	0.00166	CcSEcCtD
Gadodiamide—Pruritus—Doxorubicin—liver cancer	0.00157	0.00165	CcSEcCtD
Gadodiamide—Vomiting—Epirubicin—liver cancer	0.00152	0.0016	CcSEcCtD
Gadodiamide—Diarrhoea—Doxorubicin—liver cancer	0.00152	0.00159	CcSEcCtD
Gadodiamide—Rash—Epirubicin—liver cancer	0.00151	0.00158	CcSEcCtD
Gadodiamide—Dermatitis—Epirubicin—liver cancer	0.00151	0.00158	CcSEcCtD
Gadodiamide—Headache—Epirubicin—liver cancer	0.0015	0.00157	CcSEcCtD
Gadodiamide—Dizziness—Doxorubicin—liver cancer	0.00146	0.00154	CcSEcCtD
Gadodiamide—Nausea—Epirubicin—liver cancer	0.00142	0.00149	CcSEcCtD
Gadodiamide—Vomiting—Doxorubicin—liver cancer	0.00141	0.00148	CcSEcCtD
Gadodiamide—Rash—Doxorubicin—liver cancer	0.0014	0.00147	CcSEcCtD
Gadodiamide—Dermatitis—Doxorubicin—liver cancer	0.0014	0.00146	CcSEcCtD
Gadodiamide—Headache—Doxorubicin—liver cancer	0.00139	0.00146	CcSEcCtD
Gadodiamide—Nausea—Doxorubicin—liver cancer	0.00132	0.00138	CcSEcCtD
